Chester County News and Community Website
NORRISTOWN, PA — A 12% surge in people admitted to Gaudenzia Inc., the largest no-profit treatment provider for people with substance use and co-occurring disorders in the Northeast, in the …
Gaudenzia Unveils 2023 Frontline Report: Substance Use Disorder Trends Surge in Pennsylvania, Delaware, Maryland, and Washington D.C. Read More
PLYMOUTH MEETING, PA — Braeburn announced recently that BRIXADI (buprenorphine) extended-release injection for subcutaneous use (CIII), a new weekly and monthly medication for moderate to severe opioid use disorder (OUD) …
BRIXADI (buprenorphine) Extended-Release Injection for Subcutaneous Use (CIII) is Now Available in the U.S. for the Treatment of Moderate to Severe Opioid Use Disorder Read More
The U.S. Department of Health and Human Services (HHS), through the Substance Abuse and Mental Health Services Administration (SAMHSA), has recently awarded more than $88 million in its continuing effort …
$88 Million in Grants Awarded to Safeguard Youth Mental Health, Expand Access to Treatment for Substance Use Disorders Read More
The U.S. Food and Drug Administration recently announced new steps to help facilitate innovation in devices intended to treat opioid use disorder (OUD). The draft guidance, to help sponsors design …
FDA Takes Steps to Boost Innovations in Treating Opioid Use Disorder: New Guidance and Initiatives Read More
The Department of Health and Human Services (HHS), through its Substance Abuse and Mental Health Services Administration (SAMHSA), recently announced awards for five grant programs devoted to combating multiple facets …
HHS Announces $47.8 Million in Grants to Combat Substance Misuse and Overdose Epidemic Read More
The U.S. Food and Drug Administration announced it recently approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD). Brixadi …
FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder Read More PLYMOUTH MEETING, PA — Braeburn this week announced that the U.S. Food and Drug Administration (FDA) has approved BRIXADI (buprenorphine) extended-release injection for subcutaneous use (CIII), a new weekly and …
Braeburn’s BRIXADI (buprenorphine) Extended-Release Subcutaneous Injection (CIII) Receives FDA Approval for Moderate to Severe Opioid Use Disorder Read More
ROYERSFORD, PA — State Sen. Katie Muth (D-Chester/Montgomery/Berks) recently announced that five initiatives to enhance public safety and protect against opioid-use disorder in Senate District 44 were awarded over $1 …
East Whiteland Township Receives $200,000 for Surveillance Cameras Read More
PENNSYLVANIA — The Pennsylvania Department of Drug and Alcohol Programs (DDAP) announced Secretary Jen Smith has been awarded the American Association for the Treatment of Opioid Dependence (AATOD), Inc.’s Nyswander/Dole …
DDAP Secretary Earns Prestigious Marie Nyswander/Dole Award for Opioid Treatment Work Read More
KENNETT SQUARE, PA — State Rep. Christina Sappey is reminding constituents that she will be hosting a free Community Naloxone Training from 2 p.m. to 3:30 p.m. Monday, September 26 at …
ICYMI: Free Community Naloxone Training, September 26 Read More